Avastin Phase III Trial Meets Endpoint: PFS in Platinum-Sensitive Ovarian Cancer
Iniparib Doesn’t Meet Survival, PFS Endpoints In Phase III Trial in Triple-Negative Breast Cancer
Sentinel Node Disection No Worse Than Axillary
Triple-Negative Breast Cancer Equally Aggressive in Whites
RG7204 Meets Endpoints Of Extending Survival, PFS
INSPIRE Enrollment Stopped; Thromboembolism Risk Cited
Tarceva Reaches Endpoint Early: Longer PFS Than Chemo Alone
mTOR Inhibitor Improves PFS In Metastatic Sarcoma Patients
Afinitor Tablet Doubles PFS; Lowers Progression Risk 65%
Study Links Native American Ancestry to Leukemia Relapse
Study Explores Reasons Women Avoid Mammograms
Hormone Therapy At Menopause Linked to More Breast Cancer Risk
Children of Male Cancer Survivors Have Highrt Risk of Birth Defects
Study Finds No Link Between Tumor Grade and Relapse Risk
Clinical Trials Approved By NCI CTEP Last Month
Rituxan Approved as Maintenance For Advanced Follicular Lymphoma
Trending Stories
- In 1971, Chris Lundy had minute odds of survival. He is now the longest living BMT recipient at the Hutch
- Lei Zheng named executive director of Mays Cancer Center
- Murphy, McKay, Nodora, Ballantyne, Stupack named associate directors at UCSD Moores
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- Infections are a major cause of death in patients treated with CAR T-cell therapy
Meta-analysis focused on causes of death, excluding relapse, recurrence - NCI’s new chief data scientist Warren Kibbe tells us about efforts to get “AI-ready”
“All research now involves data science at some level.”
